Supply and Marketing Synergy Leveraging 80% Pharmacy Network

Maintaining Over 60% Market Share in the Antihistamine Segment

Zioyoung has continued its growth for three consecutive years in the sales of the allergy medication Zyrtec.

ZIOYOUNG is conducting total marketing for the allergy treatment Zyrtec. ZIOYOUNG

ZIOYOUNG is conducting total marketing for the allergy treatment Zyrtec. ZIOYOUNG

View original image

Zioyoung announced on April 6 that cumulative sales of Zyrtec over the three-year period from 2023 to 2025 reached approximately 8.01 million units. Since 2023, Zioyoung has been operating the distribution and marketing of Zyrtec in an integrated manner in collaboration with UCB Korea.


Annual sales volumes increased from 2.6 million units in 2023, to 2.63 million units in 2024, and 2.78 million units in 2025. Compared to 2022 (approximately 2.2 million units), before the introduction of total marketing, this represents an average annual growth of about 8.1%.


Industry experts believe that the strategy of combining pharmacy distribution networks with marketing efforts has contributed to increased sales.


Zioyoung has leveraged its distribution network, which does business with more than 80% of the nation's approximately 25,000 pharmacies, to align supply and sales activities with seasonal demand.


Additionally, it is analyzed that brand campaigns and the provision of disease information tailored to the spring and fall allergy seasons have helped expand consumer touchpoints.


Zyrtec currently maintains a market share in the 60% range based on sales in the domestic antihistamine market, retaining its long-held position as the top-selling product.



Chosun Hye, Chairwoman of Zioyoung, stated, "Surpassing 8 million units of Zyrtec demonstrates the successful synergy that can be achieved in the domestic OTC market when distribution and marketing are combined—a case in point for the total marketing strategy. We will continue to nurture competitive OTC brands."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing